MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up
MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up
Sleep, diet, exercise, and stress: these are factors known to change a persons risk of developing numerous non-communicable diseases. Such lifestyle impacts on healthbeneficial or harmfulexert much of their influence via inflammation.
Widespread testing, even of those not showing symptoms, is one of the most effective ways to track the prevalence of coronavirus infections in communities. The broad-based assays currently being ramped up by many hospitals and health systems around the country require a steady stream of single-use supplies.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medical Officer
MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) --Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1The AJRCCM, commonly known as The Blue Journal, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine. Background The study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7). Animals were monitored and supported for 24 hours, at which time the study concluded
Stem Cell Research is dedicated to publishing high-quality manuscripts focusing on the biology and applications of stem cell research.
Biotech company Mogrify is deploying its proprietary direct cellular conversion technology to develop cell therapies in a variety of disease areas, including auto-immune, musculoskeletal, respiratory diseases and in cancer immunotherapy.The platform utilizes data from next-generation sequencing and cellular networks to identify transcription factors or small molecules required to directly convert a cell, addressing key challenges that are typically associated with the safety and efficacy of cell therapies.Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn more about the platform, the challenges encountered in developing cell therapies, and to gain Mogrify's insights on the future of this exciting research space.Molly Campbell (MC): What were some of the major highlights for Mogrify in 2019?Joe Foster (JF): In the past year, Mogrify has solidified its reputation as a pioneer in the expanding field of cell therapy. Using a systematic, data-driven approach, our innovative cell conversion platform addresses many of the challenges impeding systematic discovery, process development and the manufacturing processes.At an operational level, Mogrify has seen unprecedented growth in the last year, with emphasis on world-class science.
Complete study of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape.
Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S.
NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027. Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
Recent Comments